Editas Medicine Announces First Quarter 2023 Results and Business Updates : vimarsana.com

Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress and in a Company-sponsored webinar On track to dose 20... | May 5, 2023

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , New York , Germany , America , Las Vegas , Linea Aspesi , Emma Reeve , Vivo Hemoglobinopathies , Gilmore Oneill , European Hematology Association , Amgen , Business Development Other Corporate , Nasdaq , Shoreline Biosciences Inc , Exchange Commission , Broad Institute , Harvard University Cas , Drug Administration , Health Care Conference , Bristol Myers Squibb , Business Development , Editas Medicine Inc , European Hematology Association Congress , Broad Institute Cas , Annual Meeting , Elliott Levy , Gilmoreo Neill , Chief Executive Officer , Sickle Cell Disease , Orphan Drug Designation , Transfusion Dependent Beta Thalassemia , Shoreline Biosciences , Editas Medicine , Essential Gene Exon Knock In , Editas Board , Editas Medicine Board , Bristol Myers , Chief People , Hematology Association , America Securities , Markets Global Healthcare Conference , Harvard University , Private Securities Litigation Reform Act , Annual Report , Nc Stock Exchange , News , Nformation , Ress Release , Ompany , O , Rovide , Linical , Pdate , N , He , Hase , Uby , Rial , Or , Cd , Une , T , Uropean , Ematology , Ssociation , Ongress , Nd , Ebinar , Rack , Ose Edit Us28106w1036 ,